Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oltipraz in Non-Alcoholic Fatty Liver Disease
NCT04142749Phase 3Completed
- Sponsor
- PharmaKing
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-alcoholic fatty liver disease (NAFLD) comparing Oltipraz with Placebo (2 arms). Primary endpoint: Variation of liver fat assessed by MRS at 24 weeks. Started Nov 2019; status: completed.
02
Drugs
oltipraz
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04142749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04142749.